Epalrestat (ONO-2235)

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Epalrestat (ONO-2235)	Purity：98% min
CAS NO：82159-09-9	Solubility：DMSO : ≥ 3.2 mg/mL (10.02 mM)
Molecular Formula：C₁₅H₁₃NO₃S₂	Package：Package according to customer requirements
Molecular Weight：319.399	Storage：Store at -20℃

Quality control

Remarks

Epalrestat is an aldose reductase inhibitor that is currently available for the treatment of diabetic neuropathy. In vivo, Epalrestat treatment significantly ameliorated the bleomycin-mediated histological fibrosis alterations and blocked collagen deposition concomitantly with reversing bleomycin-induced expression up-regulation of TGF-β1, AR, α-SMA and collagen I (both mRNA and protein).

Properties:

Appearance & Physical State: Deep red acicular crystal

Density: 1.43 g/cm3

Boiling Point: 516.8ºC at 760 mmHg

Melting Point: 210-217ºC

Flash Point: 266.4ºC

Refractive Index: 1.705

Carbohydrate Metabolism Inhibitors Related Products:

Lonidamine; LY-2608204; Acarbose ; Voglibose

References

[1]. Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55.

[2]. Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64.